A Phase IIb, 96 Week, Randomized, Partially Double-Blinded, Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of GW873140 in Combination With Combivir (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Aplaviroc (Primary) ; Efavirenz; Lamivudine/zidovudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ASCENT
- Sponsors GlaxoSmithKline; GSK
- 31 Jul 2021 This trial has been completed in Spain according to European Clinical Trials Database record (Global end date: 23 July 2006).
- 20 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
- 18 Oct 2005 New trial record.